Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...
Light Horse’s CEO said the biotech’s initial focus will be on “high-value and historically challenging” oncology targets.
Tenvie Therapeutics is making hay from an R&D shift at Denali Therapeutics, acquiring several of its neuroscience drug ...
Light Horse Therapeutics is off to the races, rounding up a $62 million series A and tacking on a Novartis partnership that ...
Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...
About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...
Advancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseasesLed by expert R&D ...
Healthcare-focused SaaS firm Innovaccer Inc. has secured $275 million in funding from investors including B Capital Group and ...